DECA PHARM 250
Nandrolone combination Injection 250 mg/ml
DECA PHARM 250 (Nandrolone combination Injection 250 mg/ml) is Clear, pale yellow, oily liquid for Intramuscular administration. Each ml contains Nandrolone Decanoate 250 mg.
Nandrolone is chemically related to Testosterone and shows enhanced anabolic and a reduced androgenic activity. In humans Nandrolone Decanoate Injection has shown to positively influence calcium metabolism and to increase bone mass in osteoporosis. Androgenic effects (e.g. virilisation) are relatively uncommon at the recommended dosages. Nandrolone lacks the C17 alpha-alkyl group which is associated with the occurrence of liver dysfunction and cholestasis.
Indications and Usage
Osteoporosis, catabolic states, renal insufficiency to counteract glucocorticoid, Suboptimal growth in children, Hypoplastic, Hemolytic or malignancy associated anaemia, to enhance physical ability in athletes, Chronic debilitating diseases especially in elderly patients to correct defective protein metabolism.
Dosage and Administration
Nandrolone Decanoate injection is intended for deep intramuscular injection only, into the gluteal muscle preferably. Dosage should be based on therapeutic response and consideration of the benefit to risk ratio. Duration of therapy will depend on the response of the condition and the appearance of adverse reactions. If possible, therapy should be intermittent. Nandrolone Decanoate should be regarded as adjunctive therapy and adequate quantities of nutrients should be consumed in order to obtain maximal therapeutic effects. For example, when it is used in the treatment of refractory anaemia, adequate iron intake is required for a maximal response. A dose of 50 to 100 mg per week is recommended for women and 100 to 250 mg per week for men. Drug therapy should be discontinued if no hematologic improvement is seen within the first six months. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit. Anemia of Renal Disease A dose of 50 to 100 mg per week is recommended for women and 100 to 200 mg per week for men. Drug therapy should be discontinued if no hematologic improvement is seen within the first six months. For children from 2 to 13 years of age, the average dose is 25 to 50 mg every 3 to 4 weeks. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.
Hepatic Hepatocellular neoplasms and peliosis hepatis have been reported in association with long-term androgenic anabolic steroid therapy.
Prepubertal: Phallic enlargement and increased frequency of erections. b. Postpubertal: Inhibition of testicular function,
testicular atrophy and oligospermia, impotence, chronic priapism, epididymitis and bladder irritability.
Clitoral enlargement, menstrual irregularities.
In both sexes: Increased or decreased libido.
Habituation, excitation, insomnia, depression.
Nausea, vomiting, diarrhea.
Bleeding in patients on concomitant anticoagulant therapy
Larynx: Deepening of the voice in women.
Hair: Hirsutism and male pattern of baldness in women.
Skin: Acne (especially in women and prepubertal boys.)
Fluid and Electrolytes: Edema, retention of serum electrolytes (sodium, chloride, potassium, phosphate, calcium).
Decreased glucose tolerance, increased serum levels of low-density lipoprotein and decreased levels of high-density lipoprotein, increased creatine and creatinine excretion, increased serum levels of creatinine phosphokinase (CPK). Some virilizing changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens.
There have been no reports of acute overdosage with the anabolics. Symptomatic treatment should be there especially if there are undesirable effects such as edema, hypoglycemia in diabetics, amenorrhea.
Store in cool dry place below 25°C. Protect from light.
México Juárez Farmacéuticos S.A.